

## REMARKS/ARGUMENTS

### Summary of Amendments to the Claims

Applicants elect Claims 1-6 of Group I. Non-elected claims 7-11 have been withdrawn. Claim 12-16 have been added to more particularly define the invention. Claims 1-6 and 12-16 are under examination.

### Response to the Restriction Requirement

In the Office Action, the Examiner required restriction to one of the following inventions under 35 U.S.C. 121:

- Group I: Claims 1-6, drawn to a method of treatment using an LHRH antagonist, classified in class 514, subclass 2;
- Group II: Claims 7, drawn to LHRH antagonists, classified in class 530, subclass 300; and
- Group III: Claims 8-11, drawn to a method of making a pharmaceutical containing LHRH antagonists, classified in class 435, subclass 68.1.

In response to the restriction requirement, Applicants elect the subject matter of Group I, claims 1-6, relating to method of treatment using an LHRH antagonist. Applicants elect species cetorelix. Applicants believe that no new matter has been added. Applicants reserves the right to file the withdrawn subject matter in a subsequent application.

Based on the foregoing amendments and remarks, favorable consideration and allowance of all of the claims now present in the application are respectfully requested.

The Commissioner is authorized to charge any required fees, including any extension and/or excess claim fees, any additional fees, or credit any overpayment, to Goodwin Procter LLP Deposit Account No. 06-0923.

Respectfully submitted for Applicant,



Ann-Marie Koss (Reg. No. 54,237)  
GOODWIN PROCTER LLP  
599 Lexington Avenue  
New York, NY 10022  
(212) 459-7434